- AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF
-
The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) by administering an amine-substituted heterocyclic heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
- -
-
Paragraph 01611
(2019/05/10)
-
- AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF
-
The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) via inhibition of a methyltransfera
- -
-
Paragraph 0421-0424
(2018/07/29)
-
- HETEROCYCLIC COMPOUNDS
-
The present invention provides a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof has an BET family protein inhibitory action, and is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, idiopathic pulmonary fibrosis, psoriasis, atopic dermatitis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, systemic lupus erythematosus etc.), cancer and the like.
- -
-
Paragraph 0303
(2016/12/26)
-
- OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS
-
The present invention relates to compounds useful as bromodomain inhibitors. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compounds and compositions in the treatment of various diseases and disorders.
- -
-
Paragraph 00230
(2014/10/04)
-
- ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS
-
The present invention relates to alkynyl substituted pyrimidinyl-pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak and/or Src fa
- -
-
Page/Page column 45-46
(2013/03/26)
-
- Electrochemical C-H amination: Synthesis of aromatic primary amines via N -arylpyridinium ions
-
We have developed a new method for C-H amination of aromatic compounds based on electrochemical oxidation of aromatic compounds in the presence of pyridine followed by the reaction of the resulting N-arylpyridinium ions with an alkylamine. This new transformation serves as a powerful method for synthesizing aromatic primary amines from aromatic compounds without using metal catalysts and harsh chemical reagents. High chemoselectivity of the present method is demonstrated by C-H amination of aromatic compounds bearing a nitro group to give a key intermediate for the synthesis of VLA-4 antagonist.
- Morofuji, Tatsuya,Shimizu, Akihiro,Yoshida, Jun-Ichi
-
supporting information
p. 5000 - 5003
(2013/05/22)
-
- The Kinetics of the Reactions of Picryl Chloride with Some Substituted Anilines. Part 6. 4-Substituted and 3,4-Disubstituted Anilines
-
Arrhenius parameters have been measured for the reactions of picryl chloride with the following substituted anilines in acetonitrile: 4-X- (X = F, Cl, Br, I, Me, or OMe); 3,4-X2- (X = Cl, Br, Me, or OMe); 4-X-3-nitro- (X = F, Cl, or Me); 3-X-4-methoxy- (X = F, Cl, Br, or I); 3-fluoro-4-nitro-; and 3,4,5-trimethoxy-aniline.In the 3,4-disubstituted series the effect of two methyl groups on the free energy of activation is strictly additive, but for the rest the measured rate constants are greater than those calculated on the assumption of additivity.The results are rationalized in terms of the positions of the transition state on the reaction co-ordinate.
- Emokpae, Thomas A.,Eguavoen, Osa,Khalil-Ur-Rahman,Hirst, Jack
-
p. 832 - 834
(2007/10/02)
-